Differential Uptake of O-(2-18F-Fluoroethyl)-L-Tyrosine, L-3H-Methionine, and 3H-Deoxyglucose in Brain Abscesses

Salber, Dagmar; Stoffels, Gabriele; Pauleit, Dirk; Oros-Peusquens, Ana-Maria; Shah, N. Jon; Klauth, Peter; Hamacher, Kurt; Coenen, Heinz H.; Langen, Karl‐Josef

doi:10.2967/jnumed.107.046615

Cited by 92 publications

(58 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These differences were caused by differential uptake of the 2 tracers in different cell populations, namely by preferential uptake of 18 F-FET in GFAP-positive reactive astrocytes but correlation of 3 H-MET uptake with CD68-positive macrophage infiltration. Similar differences between 18 F-FET and 3 H-MET uptake were also observed in an experimental abscess model (15). Thus, the results of the present study confirm the observation of nonspecific uptake of 18 F-FET in brain areas with reactive astrogliosis, and 3 H-MET obviously shows additional uptake in areas with macrophage infiltration.…”

Section: Discussionsupporting

confidence: 89%

“…Animal experiments have shown that 18 F-FET, in contrast to 18 F-FDG and 3 H-methyl-L-methionine ( 3 H-MET), exhibits no uptake in inflammatory cells and in inflammatory lymph nodes, promising a higher specificity for the detection of tumor cells (13)(14)(15)(16). Nevertheless, increased uptake of 18 F-FET has been observed in single cases of brain abscesses and in a demyelinating process (17).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-³H-Methionine Uptake in Cerebral Hematomas

Salber¹,

Stoffels²,

Oros-Peusquens³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

mentioning

confidence: 99%

Comparison of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-³H-Methionine Uptake in Cerebral Hematomas

Salber¹,

Stoffels²,

Oros-Peusquens³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

“…FET-PET was demonstrated to be helpful in distinguishing between non-tumour and proliferative tumour lesion (31,34), between infectious and tumour lesion (30), or between radionecrosis and recurrent tumour (31). Following these early studies in tumour recurrence (26), several human studies assessed FET-PET performances in the initial evaluation of isolated brain tumour.…”

Section: Discussionmentioning

confidence: 99%

Combination of MRI and dynamic FET PET for initial glioma grading

Dunet¹,

Maeder²,

Lalonde³

et al. 2014

Nuklearmedizin

View full text Add to dashboard Cite

SummaryAim: MRI and PET with 18 F-fluoro-ethyl-tyrosine (FET) have been increasingly used to evaluate patients with gliomas. Our purpose was to assess the additive value of MR spectroscopy (MRS), diffusion imaging and dynamic FET-PET for glioma grading. Patients, methods: 38 patients (42 ± 15 aged, F/M: 0.46) with untreated histologically proven brain gliomas were included. All underwent conventional MRI, MRS, diffusion sequences, and FET-PET within 3±4 weeks. Performances of tumour FET time-activity-curve, early-to-middle SUVmax ratio, choline / creatine ratio and ADC histogram distribution pattern for gliomas grading were assessed, as compared to histology. Combination of these parameters and respective odds were also evaluated. Results: Tumour time-activitycurve reached the best accuracy (67%) when taken alone to distinguish between low and high-grade gliomas, followed by ADC histogram analysis (65%). Combination of timeactivity-curve and ADC histogram analysis improved the sensitivity from 67% to 86% and the specificity from 63-67% to 100% (p < 0.008). On multivariate logistic regression analysis, negative slope of the tumour FET time-activity-curve however remains the best predictor of high-grade glioma (odds 7.6, SE 6.8, p = 0.022). Conclusion: Combination of dynamic FET-PET and diffusion MRI reached good performance for gliomas grading. The use of FET-PET/MR may be highly relevant in the initial assessment of primary brain tumours.

show abstract

“…Pöpperl et al were able to distinguish recurrent tumor and RN with 100% accuracy, applying a threshold of 2.0 for LNR max , and Galldiks et al suggested that the combined evaluation of the LNR mean of 18 F-FET uptake and the pattern of the time-activity curve can differentiate brain metastasis recurrence from RN with high accuracy (70,73). The lower specificity of 11 C-MET may be explained by its higher affinity for macrophages compared with 18 F-FET as demonstrated in animal experiments (81,82). In our study, 18 F-FET uptake in GB was more intense and more heterogeneous compared to RN, see Figure 3E.…”

Section: Amino-acid Petmentioning

confidence: 99%

PET for Therapy Response Assessment in Glioblastoma

et al. 2017

View full text Add to dashboard Cite

Glioblastoma (GB) is the most malignant and the most common type of glioma in adults, accounting for 60-70% of all malignant gliomas. Despite the current therapy, the clinical course of GB is usually rapid, with a mean survival time of approximately 1 year. For therapy response assessment in GB, magnetic resonance imaging (MRI) is the method of choice. In 2010, the Response Assessment in Neuro-Oncology (RANO) was introduced, including the tumor size (in 2D) as measured on T2-weighted and Fluid Attenuated Inversion Recovery (FLAIR)-weighted images, in addition to the contrast-enhancing tumor part. Although the RANO criteria addressed some of the limitations of the previous MacDonald criteria for therapy evaluation in high-grade glioma, treatment-related side effects hamper correct response assessment. To address the above-mentioned drawbacks in the follow-up of GB, incorporating changes in tumor biology measured by advanced MRI and positron emission tomography (PET) imaging, which may precede anatomical changes of the tumor volume, is promising. Imaging biomarkers capable of predicting response at an early time point after treatment initiation are the premise of personalized treatment enabling change or GB Treatment Response Using PET 176 discontinuation of therapy to prevent ineffective treatment or adverse events of treatment. In this chapter, an overview of applicable PET tracers for the therapy response assessment in GB and the determination of tumor recurrence versus treatment-related effects is given.

show abstract

Differential Uptake of O-(2-18F-Fluoroethyl)-L-Tyrosine, L-3H-Methionine, and 3H-Deoxyglucose in Brain Abscesses

Cited by 92 publications

References 20 publications

Comparison of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-³H-Methionine Uptake in Cerebral Hematomas

Comparison of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-³H-Methionine Uptake in Cerebral Hematomas

Combination of MRI and dynamic FET PET for initial glioma grading

PET for Therapy Response Assessment in Glioblastoma

Contact Info

Product

Resources

About

Differential Uptake of O-(2-18F-Fluoroethyl)-L-Tyrosine, L-3H-Methionine, and 3H-Deoxyglucose in Brain Abscesses

Cited by 92 publications

References 20 publications

Comparison of O-(2-18F-Fluoroethyl)-l-Tyrosine and l-3H-Methionine Uptake in Cerebral Hematomas

Comparison of O-(2-18F-Fluoroethyl)-l-Tyrosine and l-3H-Methionine Uptake in Cerebral Hematomas

Combination of MRI and dynamic FET PET for initial glioma grading

PET for Therapy Response Assessment in Glioblastoma

Contact Info

Product

Resources

About

Comparison of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-³H-Methionine Uptake in Cerebral Hematomas

Comparison of O-(2-¹⁸F-Fluoroethyl)-l-Tyrosine and l-³H-Methionine Uptake in Cerebral Hematomas